The latest experimental work published and popularised by MedicalXpress points to an interesting mechanism by which a compound found in broccoli – sulforaphane – can affect colon cells. This is not a “miracle food”, but a biologically very active molecule whose effects have been relatively well researched at the cellular and animal model level.
Sulforaphane is produced from glucoraphanin (naturally present in broccoli) by the action of the enzyme myrosinase. It belongs to the isothiocyanates and is known primarily for activating the transcription factor Nrf2 (nuclear factor erythroid 2–related factor 2).
A study by Kensler et al., published in the Proceedings of the National Academy of Sciences, states that sulforaphane is “a potent inducer of phase 2 detoxification enzymes” and significantly increases the expression of protective enzymes such as NQO1 and glutathione-S-transferase. In experimental models, this led to increased cellular protection against carcinogens.
In preclinical models of colorectal cancer, it has been repeatedly demonstrated that:
– reduction in tumour
cell proliferation – increase in apoptosis
(programmed cell death) – modulation of inflammatory pathways (NF-κB)
– influence on the intestinal microenvironment
For example, a study published in Cancer Prevention Research reports that sulforaphane reduced the number of adenomas by approximately 40–50% in mice prone to developing intestinal tumours, compared to the control group (depending on the dose and model).
Another study published in Clinical Cancer Research showed that sulforaphane can also target cancer stem-like cells, a subpopulation of cells associated with tumour recurrence and resistance to treatment.
However, it should be emphasised that most of this data comes from laboratory in vivo models. Direct clinical evidence on the treatment or prevention of colorectal cancer in humans is still limited.
Sulforaphane:
– activates Nrf2 → increases antioxidant production (glutathione)
– suppresses NF-κB → reduces chronic inflammation
– influences epigenetics (inhibition
of HDAC enzymes) – promotes apoptosis of tumour cells
The epigenetic effect (HDAC inhibition) is particularly interesting because it suggests that sulforaphane can alter gene expression without changing the DNA sequence – which is a very promising direction for research in cancer prevention.
Epidemiological studies have long shown that higher intake of cruciferous vegetables (broccoli, kale, cabbage) is associated with a lower risk of certain types of cancer, including colorectal cancer. However, this is a correlation, not proof of causality.
Direct intervention clinical studies with sulforaphane in patients with colorectal cancer are still limited and tend to examine biomarkers (e.g., changes in detoxification enzymes, oxidative stress, inflammatory markers) rather than hard clinical endpoints such as survival.
It is essential to distinguish between:
Concentrated sulforaphane (e.g., standardised extracts or activated sulforaphane derived from glucoraphanin with myrosinase) can achieve doses many times higher than those found in a normal diet.
Although sulforaphane is considered safe in a dietary context, high-dose nutritional supplements:
– They do not have the same safety data as conventional vegetables
. – They may interact with treatments (chemotherapy, immunotherapy, anticoagulants)
. – They may affect drug metabolism via cytochrome P450.
There is currently no consensus that high doses of capsular sulforaphane treat or replace cancer therapy. Most clinical studies have been short-term and focused on biomarkers rather than long-term survival.
Therefore, the following applies: Concentrated sulforaphane in capsule form may be of interest in the field of prevention and support of cell protection, but it is not a registered drug for colon cancer and should not be used as a substitute for standard treatment.
Research on sulforaphane is scientifically sound and biologically convincing. The mechanisms of action – Nrf2 activation, epigenetic effects, inflammation modulation – make sense in the context of preventing chronic diseases, including colorectal cancer.
However, this does not mean that “broccoli cures cancer”. It means that bioactive substances from cruciferous vegetables represent an interesting area of research and a potential supportive tool in the field of prevention and cell protection.
MUDr. R. Lenártová, PhD., MSc.,
physician and clinical biochemist
Sources and references:
Main source – meta-analysis published in BMC Gastroenterology (2025) “Broccoli can have a protective effect against colon cancer, study reveals” – article details including data on 17 studies, more than 639,500 participants and 97,595 cases of colorectal cancer:
https://medicalxpress.com/news/2025-08-broccoli-effect-colon-cancer-reveals.html
Original study (meta-analysis) The research is cited as Bo Lai et al., “Cruciferous vegetable intake and risk of colon cancer: a dose–response meta-analysis”, published in BMC Gastroenterology, 2025, DOI: 10.1186/s12876-025-04163-9 – here is the direct DOI for quick access:
https://doi.org/10.1186/s12876-025-04163-9
Another source confirming key data – Report on the results of the same meta-analysis, including the “sweet spot” of 20–40 g per day and a protective effect of 20%:
https://www.medicalnews.pk/30-Aug-2025/cruciferous-vegetables-lower-colon-cancer-risk-study
